Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNAT-89
- Development stage
- Unknown
- Lead developer
- RNA Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous (anticipated Based On Standard LNP-mRNA Administration Routes)
01
Overview
RNAT-89 is an investigational mRNA-based therapeutic developed by RNA Therapeutics. It is a lipid nanoparticle (LNP) formulation encoding the gene for darbepoetin, designed to enable in vivo expression of this therapeutic protein. Darbepoetin is a long-acting erythropoiesis-stimulating agent (ESA) used to treat anemia. Unlike traditional biologic drugs that are manufactured and administered as proteins, RNAT-89 delivers mRNA instructions so that the patient's own cells produce darbepoetin internally. The primary indications under development are anemia due to chronic kidney disease (CKD) and anemia associated with non-myeloid malignancies where it results from myelosuppressive chemotherapy[1][2][3][4]. This approach aims to provide a more affordable and scalable alternative to current ESA therapies.
- Other names
- RNAT 89RNAT89RNAT-89BLA-761423BLA761423BLA 761423
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on RNAT-89.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNAT-89.